GLP1R and inflammatory bowel disease: Given the observed increased risk of colorectal cancer among patients receiving GLP-1 receptor agonists, clinicians should approach long-term prescribing of these agents with careful consideration, particularly in individuals with additional risk factors for colorectal cancer, such as a family history, obesity, inflammatory bowel disease, or long-standing type 2 diabetes.